AzTrials
AzTrials

Mechanical VentilationNCT07199036

Clinical Application of the Effect of Respiratory Muscles Electrical Stimulation on Weaning in Patients With Difficult Weaning of the Mechanical Ventilation

A study testing TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation) and abFES (Functional Electrical Stimulation of Abdominal Muscles) in people with Mechanical Ventilation, run by Capital Medical University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This trial evaluates whether transcutaneous diaphragmatic/phrenic nerve stimulation (TEDS), abdominal functional electrical stimulation (abFES), or their combination, accelerates and improves the quality of weaning from prolonged invasive mechanical ventilation (IMV), compared with standardized ICU care with sham… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Mechanical Ventilation
What is being tested?
TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation) and abFES (Functional Electrical Stimulation of Abdominal Muscles)
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
300 participants
Where
1 siteChina
Study dates
29 Sep 2025to 30 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Invasive mechanical ventilation ≥21 days for PMV(at least 6 hours per day); expected ≥48 h Invasive mechanical ventilation.
  • Eligible for standardized weaning protocol and SBT assessment. Informed consent by participant or legally authorized representative.

Who cannot join

  • Non-screenable/unstable arrhythmia or hemodynamics; refractory hypoxemia/hypercapnia.
  • Pacemaker/ICD not shieldable; seizure disorder uncontrolled. Recent abdominal surgery or skin breakdown at electrode sites; BMI>35; pregnancy.
  • Prone positioning; continuous deep neuromuscular blockade; investigator deems unsuitable.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Beijing Rehabilitation Hospital, Capital Medical University

    Beijing, Shijingshan District, 100144

Other trials in China

About this study

This trial evaluates whether transcutaneous diaphragmatic/phrenic nerve stimulation (TEDS), abdominal functional electrical stimulation (abFES), or their combination, accelerates and improves the quality of weaning from prolonged invasive mechanical ventilation (IMV), compared with standardized ICU care with sham stimulation.

Being tested
TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation), abFES (Functional Electrical Stimulation of Abdominal Muscles), Sham TEDS, Sham abFES
Keywords
Prolonged Mechanical Ventilation, transcutaneous phrenic nerve electrical stimulation, abdominal functional electrical stimulation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation)Device

    Per session 20 min, twice daily; 5 days/week; up to 28 days or until successful weaning.

  • abFES (Functional Electrical Stimulation of Abdominal Muscles)Device

    Per session 20 min, twice daily

  • Sham TEDSDevice

    Position/time matched; 2 Hz low-intensity sensation only; no visible contraction.

  • Sham abFESDevice

    Position/time matched; sensation only; no visible contraction.

Study groups in NCT07199036
Study groupRoleWhat they receive
ControlSham comparatorSham TEDS + Sham abFES + Standard Care
Receives: Device: Sham TEDS; Device: Sham abFES
TEDS OnlyExperimentalTEDS + Sham abFES
Receives: Device: TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation); Device: Sham abFES
abFES OnlyExperimentalabFES + Sham TEDS
Receives: Device: abFES (Functional Electrical Stimulation of Abdominal Muscles); Device: Sham TEDS
CombinedExperimentalTEDS + abFES
Receives: Device: TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation); Device: abFES (Functional Electrical Stimulation of Abdominal Muscles)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Successful Weaning (days)

    Days from randomization to first day achieving ≥48 h free from invasive mechanical ventilation (IMV).

    Measured: From randomization up to Day 28

Secondary outcomes (10)
  1. Change in Diaphragm Excursion (DE) Measured by M-mode Ultrasound from Baseline to Day 28 (cm)

    Diaphragm excursion will be measured by M-mode ultrasonography on the right hemidiaphragm. A 3.5-5.0 MHz convex probe is placed in the right subcostal region between the mid-clavicular and anterior axillary lines. The excursion (cm) during spontaneous breathe will be recorded as the average of three consecutive breaths. The outcome is the change in excursion from baseline to Day 28.

    Measured: Baseline (within 24 hours before randomization) and Day 28 after randomization

  2. Change in Diaphragm Thickening Fraction (TFdi) from Baseline to Day 28 (%)

    Diaphragm thickness will be measured in the zone of apposition of the right hemidiaphragm with a high-frequency linear probe in B-mode. Thickness at end-expiration and end-inspiration will be recorded as the average of three breaths. The diaphragm thickening fraction (TFdi, %) is calculated as: (Thickness at end-inspiration - Thickness at end-expiration) / Thickness at end-expiration × 100. The outcome is the change in TFdi from baseline to Day 28.

    Measured: Baseline to Day 28

  3. Change in Diaphragm Thickness (DT) Measured by B-mode Ultrasound from Baseline to Day 28 (mm)

    Diaphragm thickness (mm) will be measured in the zone of apposition of the right hemidiaphragm using a high-frequency linear probe (7-12 MHz) in B-mode at end-expiration. The value is the average of three consecutive breaths. The outcome is the change in diaphragm thickness from baseline to Day 28.

    Measured: Baseline to Day 28

  4. Weaning Success From Invasive Mechanical Ventilation Within 28 Days (% of Participants)

    Weaning success is defined as remaining free from invasive mechanical ventilation for at least 48 hours after extubation or tracheostomy decannulation. The outcome is the proportion of randomized participants who achieve successful weaning within 28 days after randomization.

    Measured: Up to Day 28 after randomization

  5. 28-Day In-hospital Cost From Randomization (CNY)

    Total in-hospital cost (Chinese Yuan) during the first 28 days after randomization

    Measured: exactly 28 days

  6. Change in PEF from Baseline to Day 28 (L/min)

    Measured: Baseline to Day 28

  7. Readmission

    The original protocol planned to follow up patients at 3, 6, and 12 months post-discharge for readmission. Due to a low follow-up response rate (patients lost to follow-up, transferred elsewhere, or with incomplete contact information), the available data were insufficient for reliable analysis. This outcome was therefore removed, and the study instead focuses on in-hospital clinical outcomes.

    Measured: Readmission of 3 month/6 month/ 12 month

  8. mortality

    The original protocol planned to follow up patients at 3, 6, and 12 months post-discharge for mortality. Due to a low follow-up response rate (patients lost to follow-up, transferred elsewhere, or with incomplete contact information), the available data were insufficient for reliable analysis. This outcome was therefore removed, and the study instead focuses on in-hospital clinical outcomes.

    Measured: mortality of 3 month/6 month/ 12 month

  9. Incidence of pulmonary infection

    The original protocol planned to follow up patients at 3, 6, and 12 months post-discharge for pulmonary infection. Due to a low follow-up response rate (patients lost to follow-up, transferred elsewhere, or with incomplete contact information), the available data were insufficient for reliable analysis. This outcome was therefore removed, and the study instead focuses on in-hospital clinical outcomes.

    Measured: Incidence of pulmonary infection of 3 months/ 6 months/ 12 months

  10. Ventilator-Free Days to Day 28 (VFDs-28)

    Measured: Day 0-28 after randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Sep 2025
  2. Study start29 Sep 2025
  3. Primary completion1 Nov 2025
  4. Study completion30 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
300 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07199036
Sponsor's protocol ID
2025bkky
Status last verified
Oct 2025
First submitted
29 Sep 2025
Last updated
11 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation) and abFES (Functional Electrical Stimulation of Abdominal Muscles) in people with Mechanical Ventilation, run by Capital Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Successful Weaning (days) (time frame: From randomization up to Day 28). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in